Piergiorgio Pedron - DIASORIN Senior Corporate VP and Chief Financial Officer
| 34D Stock | EUR 97.92 2.98 2.95% |
CFO
Mr. Piergiorgio Pedron has served as Senior Corporationrationrate VP and Chief Financial Officer at DiaSorin S.p.A. since April 28, 2016. He graduated summa cum laude in Economics from the Universita Cattolica del Sacro Cuore, Milano. In 2011, he joined DiaSorin S.p.A. as Group Controller, Corporationrationrate Vice President. Later he served as CFO at the North American subsidiary DiaSorin Inc for 18 months. In January 2015, he came back to Italy assuming the role of Deputy Chief Financial Officer at DiaSorin S.p.A. Previously he served as Controller for multinational companies Jabil and Hewlett Packard in North America and for De Agostini Editore S.p.A. where he held the position of Group Controller at the UK branch for 2 years. since 2016.
| Age | 48 |
| Tenure | 9 years |
DIASORIN Leadership Team
Elected by the shareholders, the DIASORIN's board of directors comprises two types of representatives: DIASORIN inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DIASORIN. The board's role is to monitor DIASORIN's management team and ensure that shareholders' interests are well served. DIASORIN's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DIASORIN's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesca Pasinelli, Independent Director | ||
| Michele Denegri, Non-Executive Deputy Chairman of the Board | ||
| Giancarlo Boschetti, Non-Executive Director | ||
| Piergiorgio Pedron, Senior Corporate VP and Chief Financial Officer | ||
| Tullia Todros, Independent Director | ||
| Elisa Corghi, Independent Director | ||
| Stefano Ronchi, Senior Corporate Vice President - Human Resources | ||
| Riccardo Fava, External Relations Director, Head of Investor Relations and Media | ||
| Giuseppe Alessandria, Lead Independent Director | ||
| Roberta Somati, Independent Director | ||
| Stefano Altara, Non-Executive Director | ||
| John Gerace, President DiaSorin Molecular LLC | ||
| Luca Melindo, Non-Executive Director | ||
| Franco Moscetti, Independent Director | ||
| Gustavo Denegri, Non-Executive Chairman of the Board | ||
| Carlo Rosa, Chief Executive Officer, Executive Director, General Manager | ||
| Fiorella Altruda, Independent Director | ||
| Monica Tardivo, Independent Director | ||
| Ugo Gay, Senior Corporate Vice President - Industrial Operations | ||
| Chen Even, Senior Corporate Vice President - Commercial Operations and Executive Director |
DIASORIN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DIASORIN a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 8.21 B | |||
| Price To Book | 4.51 X | |||
| Price To Sales | 5.18 X | |||
| Revenue | 1.24 B | |||
| EBITDA | 517.3 M | |||
| Net Income | 310.97 M | |||
| Total Debt | 1.23 B | |||
| Cash Flow From Operations | 400.66 M | |||
| Price To Earnings To Growth | 176.54 X | |||
| Number Of Employees | 29 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DIASORIN Stock
DIASORIN financial ratios help investors to determine whether DIASORIN Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DIASORIN with respect to the benefits of owning DIASORIN security.